Gallic Acid Hindered Lung Cancer Progression by Inducing Cell Cycle Arrest and Apoptosis in A549 Lung Cancer Cells via PI3K/Akt Pathway |
Ko, Eul-Bee
(Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University)
Jang, Yin-Gi (Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Kim, Cho-Won (Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Go, Ryeo-Eun (Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Lee, Hong Kyu (Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Choi, Kyung-Chul (Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) |
1 | Deshpande, A., Sicinski, P. and Hinds, P. W. (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24, 2909-2915. DOI |
2 | Gao, N., Flynn, D. C., Zhang, Z., Zhong, X. S., Walker, V., Liu, K. J., Shi, X. and Jiang, B. H. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 287, C281-C291. |
3 | Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A. and McCubrey, J. A. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603. DOI |
4 | Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C. and Gonzalez-Baron, M. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204. DOI |
5 | Chia, Y. C., Rajbanshi, R., Calhoun, C. and Chiu, R. H. (2010) Antineoplastic effects of gallic acid, a major component of Toona sinensis leaf extract, on oral squamous carcinoma cells. Molecules 15, 8377-8389. DOI |
6 | Dasari, S. and Tchounwou, P. B. (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364-378. DOI |
7 | Evan, G. I. and Vousden, K. H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348. DOI |
8 | Inoue, M., Suzuki, R., Koide, T., Sakaguchi, N., Ogihara, Y. and Yabu, Y. (1994) Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem. Biophys. Res. Commun. 204, 898-904. DOI |
9 | Ji, B. C., Hsu, W. H., Yang, J. S., Hsia, T. C., Lu, C. C., Chiang, J. H., Yang, J. L., Lin, C. H., Lin, J. J., Suen, L. J., Gibson Wood, W. and Chung, J. G. (2009) Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J. Agric. Food Chem. 57, 7596-7604. DOI |
10 | Yu, J. S. and Cui, W. (2016) Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development 143, 3050-3060. DOI |
11 | Siegel, R. L., Miller, K. D. and Jemal, A. (2019) Cancer statistics, 2019. CA Cancer J. Clin. 69, 7-34. DOI |
12 | Liang, C. Z., Zhang, X., Li, H., Tao, Y. Q., Tao, L. J., Yang, Z. R., Zhou, X. P., Shi, Z. L. and Tao, H. M. (2012) Gallic acid induces the apoptosis of human osteosarcoma cells in vitro and in vivo via the regulation of mitogen-activated protein kinase pathways. Cancer Biother. Radiopharm. 27, 701-710. DOI |
13 | Locatelli, C., Filippin-Monteiro, F. B. and Creczynski-Pasa, T. B. (2013) Alkyl esters of gallic acid as anticancer agents: a review. Eur. J. Med. Chem. 60, 233-239. DOI |
14 | Mou, H., Zheng, Y., Zhao, P., Bao, H., Fang, W. and Xu, N. (2011) Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicol. In Vitro 25, 1027-1032. DOI |
15 | Tian, X., Huang, B., Zhang, X. P., Lu, M., Liu, F., Onuchic, J. N. and Wang, W. (2017) Modeling the response of a tumor-suppressive network to mitogenic and oncogenic signals. Proc. Natl. Acad. Sci. U.S.A. 114, 5337-5342. DOI |
16 | Wang, K., Zhu, X., Zhang, K., Zhu, L. and Zhou, F. (2014) Investigation of gallic acid induced anticancer effect in human breast carcinoma MCF-7 cells. J. Biochem. Mol. Toxicol. 28, 387-393. DOI |
17 | Zhang, H. Y., Zhang, P. N. and Sun, H. (2009) Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur. J. Obstet. Gynecol. Reprod. Biol. 146, 81-86. DOI |
18 | Badhani, B., Sharma, N. and Kakkar, R. (2015) Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv. 5, 27540-27557. DOI |
19 | Cheng, H., Shcherba, M., Pendurti, G., Liang, Y., Piperdi, B. and Perez-Soler, R. (2014) Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag. 3, 67-75. DOI |
20 | Xu, J., Ji, L. D. and Xu, L. H. (2006) Lead-induced apoptosis in PC 12 cells: involvement of p53, Bcl-2 family and caspase-3. Toxicol. Lett. 166, 160-167. DOI |
21 | Bellamy, C. O. (1997) p53 and apoptosis. Br. Med. Bull. 53, 522-538. DOI |
22 | Verma, S., Singh, A. and Mishra, A. (2013) Gallic acid: molecular rival of cancer. Environ. Toxicol. Pharmacol. 35, 473-485. DOI |
23 | Rajalakshmi, K., Devaraj, H. and Niranjali Devaraj, S. (2001) Assessment of the no-observed-adverse-effect level (NOAEL) of gallic acid in mice. Food Chem. Toxicol. 39, 919-922. DOI |
24 | Sinnberg, T., Lasithiotakis, K., Niessner, H., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Campos, M., Gogel, J., Garbe, C. and Meier, F. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129, 1500-1515. DOI |
25 | Sourani, Z. M., Pourgheysari, B. P., Beshkar, P. M., Shirzad, H. P. and Shirzad, M. M. (2016) Gallic acid inhibits proliferation and induces apoptosis in lymphoblastic leukemia cell line (C121). Iran. J. Med. Sci. 41, 525-530. |
26 | Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D. and Eccles, S. A. (2012) Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 10, 29. DOI |
27 | Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. and van Bree, C. (2006) Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315-2319. DOI |
28 | Choubey, S., Varughese, L. R., Kumar, V. and Beniwal, V. (2015) Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm. Pat. Anal. 4, 305-315. DOI |
29 | Collins, K., Jacks, T. and Pavletich, N. P. (1997) The cell cycle and cancer. Proc. Natl. Acad. Sci. U.S.A. 94, 2776-2778. DOI |
30 | Decatris, M. P., Sundar, S. and O'Byrne, K. J. (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev. 30, 53-81. DOI |
31 | Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L. and Rosell, R. (2015) Non-smallcell lung cancer. Nat. Rev. Dis. Primers 1, 15009. DOI |
32 | Hemann, M. T. and Lowe, S. W. (2006) The p53-Bcl-2 connection. Cell Death Differ. 13, 1256-1259. DOI |
33 | Ihle, N. T. and Powis, G. (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol. Aspects Med. 31, 135-144. DOI |
34 | Isuzugawa, K., Inoue, M. and Ogihara, Y. (2001) Catalase contents in cells determine sensitivity to the apoptosis inducer gallic acid. Biol. Pharm. Bull. 24, 1022-1026. DOI |
35 | Zappa, C. and Mousa, S. A. (2016) Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res. 5, 288-300. DOI |
36 | Florea, A. M. and Busselberg, D. (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3, 1351-1371. DOI |
37 | Wang, R., Ma, L., Weng, D., Yao, J., Liu, X. and Jin, F. (2016) Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway. Oncol. Rep. 35, 3075-3083. DOI |
38 | Wang, X., Martindale, J. L. and Holbrook, N. J. (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435-39443. DOI |
39 | You, B. R., Kim, S. Z., Kim, S. H. and Park, W. H. (2011) Gallic acid-induced lung cancer cell death is accompanied by ROS increase and glutathione depletion. Mol. Cell. Biochem. 357, 295-303. DOI |
40 | Yousef, M. I., Saad, A. A. and El-Shennawy, L. K. (2009) Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem. Toxicol. 47, 1176-1183. DOI |
41 | Maurya, D. K., Nandakumar, N. and Devasagayam, T. P. (2011) Anticancer property of gallic acid in A549, a human lung adenocarcinoma cell line, and possible mechanisms. J. Clin. Biochem. Nutr. 48, 85-90. DOI |
42 | Jang, Y. G., Ko, E. B. and Choi, K. C. (2020) Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression. J. Nutr. Biochem. 84, 108444. DOI |
43 | Jones, E. V., Dickman, M. J. and Whitmarsh, A. J. (2007) Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem. J. 405, 617-623. DOI |
44 | Katiyar, S. K., Roy, A. M. and Baliga, M. S. (2005) Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol. Cancer Ther. 4, 207-216. DOI |
45 | Lo, C., Lai, T. Y., Yang, J. H., Yang, J. S., Ma, Y. S., Weng, S. W., Chen, Y. Y., Lin, J. G. and Chung, J. G. (2010) Gallic acid induces apoptosis in A375.S2 human melanoma cells through caspase-dependent and -independent pathways. Int. J. Oncol. 37, 377-385. |
46 | Loehrer, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704-713. DOI |
47 | Moghtaderi, H., Sepehri, H., Delphi, L. and Attari, F. (2018) Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231. Bioimpacts 8, 185-194. DOI |
48 | Zeng, M., Su, Y., Li, K., Jin, D., Li, Q., Li, Y. and Zhou, B. (2020) Gallic acid inhibits bladder cancer T24 cell progression through mitochondrial dysfunction and PI3K/Akt/NF-κB signaling suppression. Front. Pharmacol. 11, 1222. DOI |
49 | Zhao, B. and Hu, M. (2013) Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells. Oncol. Lett. 6, 1749-1755. DOI |
50 | Zhou, Y. D., Hou, J. G., Yang, G., Jiang, S., Chen, C., Wang, Z., Liu, Y. Y., Ren, S. and Li, W. (2019) Icariin ameliorates cisplatin-induced cytotoxicity in human embryonic kidney 293 cells by suppressing ROS-mediated PI3K/Akt pathway. Biomed. Pharmacother. 109, 2309-2317. DOI |
51 | Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., Spiro, S. G., Rolland, E., Fossati, R., Aubert, D., Ding, K., Waller, D. and Le Chevalier, T.; LACE Collaborative Group (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552-3559. DOI |
52 | Han, S. W. and Roman, J. (2010) Targeting apoptotic signaling pathways in human lung cancer. Curr. Cancer Drug Targets 10, 566-574. DOI |
53 | Lu, Y., Jiang, F., Jiang, H., Wu, K., Zheng, X., Cai, Y., Katakowski, M., Chopp, M. and To, S. S. (2010) Gallic acid suppresses cell viability, proliferation, invasion and angiogenesis in human glioma cells. Eur. J. Pharmacol. 641, 102-107. DOI |
54 | Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L. and Lewis, J. L., Jr. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389-393. DOI |
55 | Aborehab, N. M. and Osama, N. (2019) Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells. Cancer Cell Int. 19, 154. DOI |
56 | Antognelli, C., Frosini, R., Santolla, M. F., Peirce, M. J. and Talesa, V. N. (2019) Oleuropein-induced apoptosis is mediated by mitochondrial glyoxalase 2 in NSCLC A549 cells: a mechanistic inside and a possible novel nonenzymatic role for an ancient enzyme. Oxid. Med. Cell. Longev. 2019, 8576961. |
57 | Liu, S. L., Liu, Z., Zhang, L. D., Zhu, H. Q., Guo, J. H., Zhao, M., Wu, Y. L., Liu, F. and Gao, F. H. (2017) GSK3beta-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells. Cell Cycle 16, 2386-2395. DOI |